PRINCE

A "One-Stop Shop" for Preclinical Research & Development

A "One-Stop Shop" for Preclinical Research & Development

Industry

Big Pharma

Company

Bayer AG

Timeline

5 Months

Role

UX/UI Design

Keywords

Conversational AI

Status

Shipped

Industry

Big Pharma

Company

Bayer AG

Timeline

5 Months

Industry

Big Pharma

Company

Bayer AG

Timeline

5 Months

Role

UX/UI Design

Keywords

Conversational AI

Status

Shipped

PRINCE

🏆 Voted Bayer's Best Technical AI Product of the Year 2025

PRINCE ("Preclinical Information Center") is Bayer’s one-stop search assistant and platform for finding preclinical research data, developed in collaboration with Thoughtworks. The platform consolidates over 17,000 study reports and their metadata into a searchable, cloud-based system built on AWS. By making decades of scientific data and records easily accessible, PRINCE acts as a assistive co-pilot to help researchers design more efficient studies, speed up repetitive tasks, and accelerate the decision-making process in preclinical research and pharmaceutical drug discovery.

Building on this foundation, a generative AI chatbot was integrated onto the platform, enabling scientists and project managers to search and query sensitive, internal data in natural language. Each response is grounded in source-cited information to ensure transparency and trust. Together, PRINCE and its AI assistant aims to transform how Bayer’s teams interact with research data, turning static reports into actionable insights that support innovation across safety, toxicology, and preclinical development research, and more.

PRINCE

🏆 Voted Bayer's Best Technical AI Product of the Year 2025

PROBLEM

How might we enable researchers to retrieve and synthesize relevant scientific data with transparency, efficiency, and traceability across a historical database?

How might we enable researchers to retrieve and synthesize relevant scientific data with transparency, efficiency, and traceability across a historical database?

How might we enable researchers to retrieve and synthesize relevant scientific data with transparency, efficiency, and traceability across a historical database?

DESIGN PROCESS

(Some visual designs have been modified as per NDA requirements)

RESEARCH & DISCOVERY

User studies revealed common challenges and opportunities.

We kicked off the project with a series of user interviews on internal Bayer researchers who were already using an early release of the PRINCE chatbot. Users ranged from toxicologists, microbiologists, R&D innovation directors, and machine learning research scientists. The outcome of these user interviews were opportunities that helped to identify persona, user goals, potential use cases, and common challenges faced when interacting with PRINCE. Some questions explored included the following:

What do you consider important when making decisions?
What are your main goals when using the PRINCE chatbot?
Are there any existing features you don’t use?
What do you do with the information you receive?
Which types of questions does PRINCE assist you on?

What do you consider important when making decisions?
What are your main goals when using the PRINCE chatbot?
Are there any existing features you don’t use?
What do you do with the information you receive?
Which types of questions does PRINCE assist you on?

What do you consider important when making decisions?
What are your main goals when using the PRINCE chatbot?
Are there any existing features you don’t use?
What do you do with the information you receive?
Which types of questions does PRINCE assist you on?

Affinity Mapping identified an actionable product roadmap.

After uncovering key insights into how our users interact and leverage AI systems in their workflows, I translated the user findings into a affinity map. The goal was to identify common challenges and actionable use cases for possible features engineers could implement into the next product sprint.

Affinity mapping board identify five core clusters (in blue) for potential use cases

Affinity mapping board identify five core clusters (in blue) for potential use cases

Affinity mapping board identify five core clusters (in blue) for potential use cases

PROTOTYPES

WRITING ASSISTANT

How might we design a collaborative writing assistant to aid users in research and discovery work?

Many PRINCE users noted that they were unfamiliar using generative AI tools and needed help crafting good prompts that would lead to their desired goals. Some users were just unsure which part of their prompts needed revising. As a solution, we explored a writing assistant chatbot feature offering users follow up suggestions on their prompting, and exploring a way to build a human-in-the-loop mechanism into the user experience. The purpose of the writing assistant was to help users at various stages if their research process — whether that involves brainstorming, expanding on a topic, crafting better drafts for papers, or forming better follow up questions.

DESIGN CONCEPT

WRITING ASSISTANT

How might we design a collaborative writing assistant to aid users in research and discovery work?

Many PRINCE users noted that they were unfamiliar using generative AI tools and needed help crafting good prompts that would lead to their desired goals. Some users were just unsure which part of their prompts needed revising. As a solution, we explored a writing assistant chatbot feature offering users follow up suggestions on their prompting, and exploring a way to build a human-in-the-loop mechanism into the user experience. The purpose of the writing assistant was to help users at various stages if their research process — whether that involves brainstorming, expanding on a topic, crafting better drafts for papers, or forming better follow up questions.

DESIGN CONCEPT

Writing assistant provides follow up contextual prompts to guide users through their problems.

CONVERSATION STARTERS

What if we add starter prompts and topic modes to help onboard new users into the interface?

Since we found that new users were unsure how to begin interacting with the AI chatbot, we introduced conversation starters, a predefined, context-aware example of prompts users can select to begin their search query and initially test out the system’s capabilities. The idea was to help improve user onboarding and user confidence, reducing hesitation when adopting a new tool. Another concept we explored was introducing topic modes, a predefined agent setting to perform and solve task-based problems.

DESIGN CONCEPT / LANDING PAGE

DESIGN CONCEPT / LANDING PAGE

What if we add conversational starters and topics modes to help onboard users in?

What if we add conversational starters and topics modes to help onboard users in?

Conversational starters provided examples on what the AI system could achieve for new users.

Conversational starters provided examples on what the AI system could achieve for new users.

TRACING SOURCES

How can we offer a way for users to access the sources for each search request within the internal database?

Researchers needed transparency to trust AI-generated responses and validate the origin of retrieved information. We visualized a sources section that lists and links back to the original study report from the internal database for each derived answer. This strengthened trust, accountability, and compliance by making each LLM generated response fully traceable to a verified data source.

DESIGN CONCEPT

DESIGN CONCEPT

DEPLOYMENT PREVIEWS

What about a real-time preview log showing each decision the chatbot deploys to reach its final output?

Researchers needed greater visibility into how the AI processed their queries, as the system’s reasoning and retrieval steps were largely opaque. Therefore, a deployment preview feature was added to surface the 'behind-the-scenes' process of the LLM—showing how inputs were interpreted, data retrieved, and outputs were formed. This transparency also created space for potential human-in-the-loop interventions, allowing specialists to review or refine steps at specific stages before final results were generated.

DESIGN CONCEPT

+

New Chat

Recents

Give me a literature review on studie...

Data Table for Study A10z7 with bio...

Find me the biomarkers from Study...

Data Table for Study A88b3 from 20...

Written Report Summary for Study T8

Please draft me a ordered list of all...

Comprehensive literature review on Entrectinib inhibitors

Experiment

Give me a literature review on studies from the past 5 years about Entrectinib inhibitors for tumor-agnostic therapies

Sources

[12]

| More

PRINCE Chatbot steps

Status

Recovering files

50 potential files sourced in internal database

Keyword match

Filtering studies based on keyword match analysis

Sources: 21 found

21 matches filtered based on search and analysis

Tools: Extract data

Extracting data based on findings and metrics

Generate report

Compile all findings into final file for hand off

TRK Inhibitors...

Tissue-agnostic Anti-Cancer Drug...

TRK Inhibitors...

Zebrafish models in Toxicology an...

Pharmaceutic...

Tissue-Agnostic Targeting of NTR...

Pharmaceutic...

NCT02568267 Study of Entrecti...

Journal for Pr...

Integrated Analysis of Efficacy and S...

PRINCE Chatbot

Mechanism and Approval


Entrectinib is an orally available inhibitor targeting TRKA/B/C, ROS1, and ALK, notable for its CNS penetration capability which is critical for treating brain metastases. It has been FDA approved for adult and pediatric patients with solid tumors harboring NTRK gene fusions, based on results from integrated analyses of several clinical trials including ALKA-372-001, STARTRK-1, and STARTRK-2. These trials collectively demonstrated entrectinib's efficacy across different tumor types without regard to tissue origin, marking it as a key example of tumor-agnostic ("basket trial") drug development.

Clinical Efficacy

Entrectinib showed an objective response rate (ORR) of approximately 57% with some complete responses noted across diverse cancers with NTRK fusions. Its intracranial activity was also documented with responses observed in patients with brain metastases. The median progression-free survival (PFS) ranged around 11 months in patients treated with entrectinib. Indirect comparative analyses suggest larotrectinib may have a longer overall survival and duration of response, but entrectinib maintains a comparable overall safety profile.

Processed

Regenerate

SECRET

Ask PRINCE your follow up question here...

Writing Assistant

Results in PRINCE may need additional verification

DESIGN CONCEPT

+

New Chat

Recents

Give me a literature review on studie...

Data Table for Study A10z7 with bio...

Find me the biomarkers from Study...

Data Table for Study A88b3 from 20...

Written Report Summary for Study T8

Please draft me a ordered list of all...

Comprehensive literature review on Entrectinib inhibitors

Experiment

Give me a literature review on studies from the past 5 years about Entrectinib inhibitors for tumor-agnostic therapies

Sources

[12]

| More

PRINCE Chatbot steps

Status

Recovering files

50 potential files sourced in internal database

Keyword match

Filtering studies based on keyword match analysis

Sources: 21 found

21 matches filtered based on search and analysis

Tools: Extract data

Extracting data based on findings and metrics

Generate report

Compile all findings into final file for hand off

TRK Inhibitors...

Tissue-agnostic Anti-Cancer Drug...

TRK Inhibitors...

Zebrafish models in Toxicology an...

Pharmaceutic...

Tissue-Agnostic Targeting of NTR...

Pharmaceutic...

NCT02568267 Study of Entrecti...

Journal for Pr...

Integrated Analysis of Efficacy and S...

PRINCE Chatbot

Mechanism and Approval


Entrectinib is an orally available inhibitor targeting TRKA/B/C, ROS1, and ALK, notable for its CNS penetration capability which is critical for treating brain metastases. It has been FDA approved for adult and pediatric patients with solid tumors harboring NTRK gene fusions, based on results from integrated analyses of several clinical trials including ALKA-372-001, STARTRK-1, and STARTRK-2. These trials collectively demonstrated entrectinib's efficacy across different tumor types without regard to tissue origin, marking it as a key example of tumor-agnostic ("basket trial") drug development.

Clinical Efficacy

Entrectinib showed an objective response rate (ORR) of approximately 57% with some complete responses noted across diverse cancers with NTRK fusions. Its intracranial activity was also documented with responses observed in patients with brain metastases. The median progression-free survival (PFS) ranged around 11 months in patients treated with entrectinib. Indirect comparative analyses suggest larotrectinib may have a longer overall survival and duration of response, but entrectinib maintains a comparable overall safety profile.

Processed

Regenerate

SECRET

Ask PRINCE your follow up question here...

Writing Assistant

Results in PRINCE may need additional verification

FINAL DESIGNS

We ended on a clean, simple, and familiar user interface.

The new PRINCE interface brought forward a cleaner, user-friendly interface with simplified features. The LLMs models were also fine tuned to receive better tokens during the information retreival process, since AI hallucinations were a major concern for researchers. Users reported a more positive experience navigating the PRINCE database, and provided constructive feedback on potential feature add-on's in future iterations. 

+

+

New Chat

New Chat

Recents

Recents

New Chat

New Chat

Data Table for Study A10a7

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Find me the biomarkers related to...

Data Table for Study A88b3

Data Table for Study A88b3

Past 7 Days

Past 7 Days

Data Table for Study A10a7

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Find me the biomarkers related to...

Data Table for Study A88b3

Data Table for Study A88b3

Past 14 Days

Past 14 Days

Type message here...

Type message here...

Writing Assistant

Writing Assistant

Results in PRINCE may need additional verification

Results in PRINCE may need additional verification

SECRET

SECRET

Draft me a report

Draft me a report

Summarize

Summarize

Find Studies

Find Studies

Find Studies

Find Studies

Generate tables

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

+

New Chat

Recents

New Chat

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 7 Days

Data Table for Study A10a7

Data Table for Biomarkers from Stu...

Find me the biomarkers related to...

Data Table for Study A88b3

Past 14 Days

Type message here...

Writing Assistant

Results in PRINCE may need additional verification

SECRET

Draft me a report

Summarize

Find Studies

Find Studies

Generate tables

OUTCOMES

Impact & Awards

The new PRINCE interface was shipped and demoed at an internal Bayer showcase attracting over 500+ virtual attendees. It presented a cleaner user interface, conversation starters to help onboarding, accurate logs of intermediate steps for better transparency, as well as an updated side bar menu for conversational history. It received positive remarks from users in our test group and was also awarded Bayer's GenAI Award for the best technical implementation in early Spring 2025.

Reflections & Learnings

Overall, this project taught me that designing for AI is not about showcasing intelligence, it's about designing for human behaviour, transparency, and trust. The final PRINCE prototype transformed from a basic search tool into a trusted research collaborator, built to promote transparency, security, and a fluid human-centered user experience. Throughout this process, I collaborated closely with AI engineers, gaining a hands-on understanding of tokenization, retrieval-augmented generation (RAG), and foundational large language model (LLM) concepts to better align my product decisions for what was possible within the system's capabilities.